Rituximab is a human/mouse chimeric IgG1κ antibody ... effect profile in more than 50,000 transplant recipients. In MS patients, daclizumab is currently thought to take its therapeutic effect ...

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...

Rituximab, a chimeric monoclonal anti-CD20 IgG1 antibody, induces complement-dependent and antibody-dependent destruction of all B-lineage cells, except plasma and pre-B cells, which do not ...

State Sen. John Horhn secured the Democratic nomination and is heavily favored to become Jackson’s next mayor. After polls closed Tuesday night, Horhn received 74.75%, or 18,493 total votes in ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Use this guide to learn how B-cell therapy may help with your multiple sclerosis, along with what to consider if you’re already on it.